Back to search
FDAFDA · Food and drugs·Recall number Z-1597-2022

MAGELLAN DIAGNOSTICS LeadCare II Blood Lead Test Kit Rapid Test Kit LeadCare II General Chemistry Blood Lead Test Whole Blood Sample 48 Tests Model Number: 70-6762

Published August 31, 2022 · Recall initiated: May 25, 2022

Summary

FDA records medical device Class II recall Z-1597-2022, published August 31, 2022 and initiated May 25, 2022. Recalling firm: Mckesson Medical-Surgical Inc. Corporate Office; Status: Ongoing; Reported quantity: 81 kits; Lot: GTIN: 00850355006000. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Facility Temperature excursions (from June 2021-August 2021) prior to delivery; exposure to higher temperatures may have impacted product effectiveness. All lots received between 06/01/21-9/30/21.

What to do

Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Mckesson Medical-Surgical Inc. Corporate Office
Distributor
US Nationwide
Lot
GTIN: 00850355006000
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was MAGELLAN DIAGNOSTICS LeadCare II Blood Lead Test Kit Rapid Test Kit LeadCare II General Chemistry Blood Lead Test Whole Blood Sample 48 Tests Model Number: 70-6762 recalled?

Yes. FDA published recall Z-1597-2022 on August 31, 2022. Reported hazard: Facility Temperature excursions (from June 2021-August 2021) prior to delivery; exposure to higher temperatures may have impacted product effectiveness. All lots received between 06/01/21-9/30/21.

What should I do if I have this product?

Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit